News | Molecular Imaging | October 26, 2017

Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery

New funding from Dutch Cancer Society will allow further testing of technique to track prostate specific membrane antigen (PSMA) in real time

Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery

October 26, 2017 — The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF Kankerbestrijding) to test whether a novel molecular imaging technology can guide prostate cancer surgery. The project will evaluate the imaging technology’s ability to detect prostate cancer during surgery, with the aim of performing more accurate removal of cancerous tissue.

Prostate cancer is the most common cancer among men in Europe with over 350,000 diagnosed in Europe every year. Complete removal of malignant tissue during prostate cancer surgery can be challenging, especially in later-stage disease, as it can be difficult to distinguish between cancerous and non-cancerous tissue. Accordingly, there is a crucial need for new technologies to help surgeons visualize cancer in real time during an operation to ensure that the cancer has been completely removed.

In the joint research project, the Netherlands Cancer Institute, University of Twente and industry partners Lightpoint Medical and Philips will evaluate a novel molecular imaging technology to image the prostate cancer biomarker prostate specific membrane antigen (PSMA) during surgery. If successful, the technology will be tested in larger clinical trials, with the aim of sparing healthy tissue and reducing recurrence rates in prostate cancer surgery.

Marcel Stokkel, M.D., nuclear medicine physician at NKI, commented, “If this technique is successful, we will be able to guide the urologist in the most optimal way by combining pre-operative staging with per-operative imaging using the same tracer. If the resection margins can be assessed with highest accuracy during surgery, we might become able to improve recurrence and survival rates. The collaboration with Lightpoint Medical, Philips and the University of Twente is the most optimal setting to reach this goal and to complete this study.”

For more information: www.nki.nl

Related Content

Sectra Adds DePuy Synthes 3-D Templates to Pre-Operative Orthopedic Solution
News | Orthopedic Imaging | October 17, 2019
International medical imaging information technology (IT) and cybersecurity company Sectra is extending its pre-...
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the
Brainlab Introduces Loop-X Mobile Intraoperative Imaging Robot
News | Mobile C-Arms | September 26, 2019
Digital medical technology company Brainlab unveiled Loop-X, which it calls the first mobile intraoperative imaging...
Virtual Reality 3-D Models Help Yield Better Surgical Outcomes

Joseph Shirk, M.D., of UCLA with the virtual reality headset. Image courtesy of UCLA Jonsson Comprehensive Cancer Center

News | Virtual and Augmented Reality | September 25, 2019
A UCLA-led study has found that using three-dimensional virtual reality (VR) models to prepare for kidney tumor...
High-dose Radiation Effective for Men Whose Prostate Cancer Has Spread
News | Prostate Cancer | September 23, 2019
A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along